rnai: search

Benitec receives RNAi patent in New Zealand

Benitec Limited announced that a key patent focused on producing Double-Stranded Nucleic Acid constructs for therapeutic and related applications of RNA interference (RNAi) was granted in New Zealand.

Alnylam Forms Collaboration with Max Planck Institute to Investigate Mechanisms for Cellular Uptake of RNAi Therapeutics

Alnylam Forms Collaboration with Max Planck Institute to Investigate Mechanisms for Cellular Uptake of RNAi Therapeutics

Silence Therapeutics Receives Allowance from United States Patent and Trademark Office for its Core RNAi Patent

Silence Therapeutics Receives Allowance from United States Patent and Trademark Office for its Core RNAi Patent

Silence Therapeutics Receives Allowance from United States Patent and Trademark Office for its Core RNAi Patent

Silence Therapeutics Receives Allowance from United States Patent and Trademark Office for its Core RNAi Patent

Silence Therapeutics US Patent Update

LONDON - 30 July 2008 - Silence Therapeutics plc (AIM: SLN), a leading European RNAi focused biotechnology company, announces that the US Patent and Trademark Office has indicated on its official website that patent application 10/633,630, Silence's core RNAi patent application, has been allowed. The Company will make a further announcement once the official information has been reviewed.

Tekmira Pharmaceuticals Announces RNAi Research Collaboration with Bristol-Myers Squibb

Tekmira Pharmaceuticals Corporation announced a research collaboration with Bristol-Myers Squibb using Tekmira's SNALP technology to deliver small interfering RNAs (siRNAs) to specific organs and tissues outside of the liver.

Tekmira Pharmaceuticals Announces RNAi Research Collaboration With Bristol-Myers Squibb

Tekmira Pharmaceuticals Corporation (TSX:TKM) announced today a research collaboration with Bristol-Myers Squibb (NYSE:BMY) using Tekmira's SNALP technology to deliver small interfering RNAs (siRNAs) to specific organs and tissues outside of the liver.

Researchers Halt Spread Of HIV With RNAi In Animal Model

Hopes languished last September when a promising candidate HIV vaccine failed to work. Despite this setback, many researchers still believe immunization is possible, and a new study suggests they're correct—at least at the cellular level.

Researchers halt spread of HIV with RNAi

BOSTON, Mass. (Aug. 7, 2008) — Hopes languished last September when a promising candidate HIV vaccine failed to work. Despite this setback, many researchers still believe immunization is possible, and a new study suggests they're correct—at least at the cellular level.

MDRNA, Inc. Completes Exclusive License Agreement to RNAi Delivery Peptides

MDRNA, Inc. (Nasdaq: MRNA) announced today that it has signed an exclusive license agreement to intellectual property from the University of Michigan covering cationic peptides for enhanced delivery of nucleic acids. Terms of the agreement were not disclosed.

Silence Therapeutics receives notice of allowance for RNAi patent

Broadband Service Provider Trident SR Sdn. Bhd.

Silence Therapeutics Receives Allowance from United States Patent and Trademark Office for its Core RNAi Patent

U.S. AtuRNAi patent allowance builds on European equivalent granted in 2007, expanding commercial protection

Silence Therapeutics Receives Allowance from United States Patent and Trademark Office for its Core RNAi Patent

U.S. AtuRNAi Patent Allowance Builds on European Equivalent Granted in 2007, Expanding Commercial Protection LONDON, July 31

Health Robotics Announces a New Exclusive Partnership for its CytoCare(TM) Robot and a Review of its Customer Adoption and Sales Operations Worldwide Over the Last 12 Months

ANTIBIOTICS ENHANCE RNAI CAPABILITIES - Interview with Peng Jin, Ph.D., Assistant Professor, Department of Human Genetics, Emory University School of Medicine ...MORE

Philips New Handheld Ultrasound System Offers Premium Image Quality in a Portable System

ANTIBIOTICS ENHANCE RNAI CAPABILITIES - Interview with Peng Jin, Ph.D., Assistant Professor, Department of Human Genetics, Emory University School of Medicine ...MORE

Red Hat Enterprise Linux Receives Department of Defense IPv6 Certification

ANTIBIOTICS ENHANCE RNAI CAPABILITIES - Interview with Peng Jin, Ph.D., Assistant Professor, Department of Human Genetics, Emory University School of Medicine ...MORE

AnswerCo Introduces Revenue-Generating Widget for Bloggers

ANTIBIOTICS ENHANCE RNAI CAPABILITIES - Interview with Peng Jin, Ph.D., Assistant Professor, Department of Human Genetics, Emory University School of Medicine ...MORE

Benitec Limited (ASX:BLT) Announce Double-Stranded Patent Granted In New Zealand

http://www.abnnewswire. %20com/en>) - Benitec Limited (ASX:BLT)(PINK:BNIKF) today announced that a key patent focused on producing Double-Stranded Nucleic Acid constructs for therapeutic and related applications of RNA interference (RNAi) was granted in New Zealand.

::: Benitec Limited (ASX:BLT) Announce Double-Stranded Patent Granted In New Zealand

Melbourne, Australia, Aug 8, 2008 - (ABN Newswire) - Benitec Limited (ASX:BLT)(PINK:BNIKF) today announced that a key patent focused on producing Double-Stranded Nucleic Acid constructs for therapeutic and related applications of RNA interference (RNAi) was granted in New Zealand.

Benitec Limited (ASX:BLT) Announce Double-Stranded Patent Granted In New Zealand

2008-08-07Â 23:32Â ET - News Release Melbourne, Australia, Aug 8, 2008 - (ABN Newswire) - Benitec Limited (ASX:BLT)(PINK:BNIKF) today announced that a key patent focused on producing Double-Stranded Nucleic Acid constructs for therapeutic and related applications of RNA interference (RNAi) was granted in New Zealand.

Calando Patent Issued for Active Ingredient of Lead siRNA Drug Candidate, CALAA-01

Calando Pharmaceuticals, Inc. ("Calando"), a majority-owned subsidiary of Arrowhead Research Corporation (NASDAQ: ARWR), announced today the issuance of U.S. Patent No. 7,427,605, entitled, "Inhibitors of ribonucleotide reductase subunit 2 and uses thereof." The patent contains claims directed to inhibitory nucleic acid sequences targeting the Ribonucleotide Reductase Subunit 2 ("R2") gene, as well as pharmaceutical compositions and methods for inhibiting tumor growth utilizing the sequences. R2 is the gene targeted by Calando's lead siRNA-containing nanoparticle therapeutic, CALAA-01, which is currently in a Phase I clinical trial for patients with non-resectable or metastatic solid tumors. CALAA-01 is the only RNAi therapeutic for cancer to have reached the clinic.

Search took 0.02 seconds.